NL-OMON47924已完成不适用
Observational study to evaluate pharmacokinetics and pharmacodynamics of docetaxel, paclitaxel, doxorubicin, gemcitabine, vinorelbine, and capecitabine in elderly patients. - SENIOR (Study to Evaluate Neoplasmatic drugs In Older Recipients)
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 337 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 337
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Planned to receive docetaxel, paclitaxel, doxorubicin, gemcitabine, vinorelbine, or capecitabine as regular treatment for cancer; 2. Age >= 70 years; 3. Able and willing to give written informed consent prior to participation in the trial; 4. Able and willing to undergo blood sampling for pharmacokinetics.
排除标准
- •No exclusion criteria are applicable.
研究者
相似试验
招募中
Unknown
An observational study to determine the relationship between blood concentrations of Nintedanib and the safety of the drug in the real world.interstitial pneumoniaJPRN-UMIN000052260Hamamatsu University School of Medicine100
已完成
不适用
A clinical study to evaluate the pharmacokinetics of colistin and to explore biomarkers for nephrotoxicity in healthy volunteersKCT0005944Kyung Hee University Hospital12
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-000535-36-CZAbbott GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-000535-36-DEAbbVie Deutschland GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisEUCTR2012-000535-36-PLAbbott GmbH & Co. KG100